R. W. Chen Et Al. , "Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma (HL): Impact of cycle 2 PET result on modified progression-free survival (mPFS).," JOURNAL OF CLINICAL ONCOLOGY , vol.36, no.15, 2018
Chen, R. W. Et Al. 2018. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma (HL): Impact of cycle 2 PET result on modified progression-free survival (mPFS).. JOURNAL OF CLINICAL ONCOLOGY , vol.36, no.15 .
Chen, R. W., Ansell, S. M., Gallamini, A., Connors, J. M., Savage, K. J., Collins, G. P., ... Grigg, A.(2018). Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma (HL): Impact of cycle 2 PET result on modified progression-free survival (mPFS).. JOURNAL OF CLINICAL ONCOLOGY , vol.36, no.15.
Chen, Robert Et Al. "Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma (HL): Impact of cycle 2 PET result on modified progression-free survival (mPFS).," JOURNAL OF CLINICAL ONCOLOGY , vol.36, no.15, 2018
Chen, Robert W. Et Al. "Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma (HL): Impact of cycle 2 PET result on modified progression-free survival (mPFS).." JOURNAL OF CLINICAL ONCOLOGY , vol.36, no.15, 2018
Chen, R. W. Et Al. (2018) . "Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma (HL): Impact of cycle 2 PET result on modified progression-free survival (mPFS).." JOURNAL OF CLINICAL ONCOLOGY , vol.36, no.15.
@article{article, author={Robert W. Chen Et Al. }, title={Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma (HL): Impact of cycle 2 PET result on modified progression-free survival (mPFS).}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2018}